The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Mikhail
0000-0001-6552-8023
M
Fominykh
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Vasily
V
Shuvaev
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Irina
I
Martynkevich
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Lyubov
L
Polushkina
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Vera
V
Udaleva
Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.
Kudrat
K
Abdulkadyrov
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines; D019233:Retreatment; D016896:Treatment Outcome
D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D003561:Cytarabine; C540383:ruxolitinib; D015122:Mercaptopurine
Ruxolitinib; blast phase; combination treatment regimen; myelofibrosis